Thyroid Cancer Drugs Market Report 2026

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.32 billion in 2025 to $1.47 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising thyroid cancer incidence, adoption of kinase inhibitors, improved cancer diagnostics, expansion of oncology hospitals, increasing access to targeted therapies.

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growth in personalized oncology drugs, rising incidence of advanced thyroid cancer, increasing clinical trial activity, expansion of immunotherapy combinations, higher oncology healthcare spending. Major trends in the forecast period include rising adoption of targeted multikinase therapies, increasing use of combination drug regimens, growing focus on advanced and refractory thyroid cancer, expansion of precision oncology treatment approaches, increased hospital-based thyroid cancer management.

Rising cases of thyroid cancer are anticipated to fuel the expansion of the thyroid cancer drugs market in the future. Thyroid cancer involves cancerous growths in the thyroid gland, necessitating prompt diagnosis and potent treatments to halt progression and spread. This uptick stems from both enhanced detection via advanced imaging and diagnostics, as well as greater exposure to environmental risks. The growing prevalence of thyroid cancer bolsters the drugs market by heightening demand for precision therapies, immunotherapies, radiopharmaceuticals, and hormone-inhibiting drugs that improve results and survival rates. For instance, in September 2025, Cancer Research United Kingdom - a UK nonprofit dedicated to cancer research and support - forecasted about 6,600 annual thyroid cancer cases by 2038-2040, with rates climbing 27% from roughly 7.3 per 100,000 people yearly in 2024-2026 to around 9.2 per 100,000. Thus, the surge in thyroid cancer incidences is propelling the thyroid cancer drugs market forward.

Leading companies in the thyroid cancer market are developing innovative therapies like selpercatinib to enhance patient treatment options and results. Selpercatinib, sold under the brand Retevmo, is a drug designed to treat cancers linked to Rearranged During Transfection (RET) mutations, such as advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, Eli Lilly and Company, a pharmaceutical firm based in the US, gained approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), the US federal agency responsible for public health protection, to treat advanced or metastatic MTC with a RET mutation. This approval covers both adult and pediatric patients aged 2 years and older who need systemic treatment. The recent traditional approval represents a major step forward in therapies for this particular thyroid cancer type.

In October 2024, Sanofi, a France-based pharmaceutical company, teamed up with Orano Med to push forward next-generation radioligand therapies for rare cancers, such as thyroid cancer. The partnership merges Sanofi’s strengths in drug development with Orano Med’s know-how in lead-212 (212Pb) alpha-emitting isotope-based radioligand therapies, targeting the discovery, design, and clinical advancement of innovative treatments. Orano Med, a France-based biotech firm focused on oncology, leads in targeted alpha therapies and specializes in radioligand treatments for rare cancers.

Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH.

North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thyroid cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported oncology APIs and biologics used in targeted thyroid cancer therapies, including multikinase inhibitors and advanced biologic treatments. The impact is most evident in specialized therapy segments and hospital procurement channels, where pricing and supply continuity are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on cross border oncology supply chains. Rising tariff related expenses have influenced procurement planning, reimbursement considerations, and treatment pricing. However, tariffs have supported domestic manufacturing, expanded local production capacity, and strengthened regional oncology drug supply chains over the long term.

The thyroid cancer drugs market research report is one of a series of new reports that provides thyroid cancer drugs market statistics, including thyroid cancer drugs industry global market size, regional shares, competitors with a thyroid cancer drugs market share, detailed thyroid cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. This thyroid cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thyroid cancer drugs are medications used to treat thyroid cancer by inhibiting various kinase proteins. These drugs work mainly in two ways. First, they help stop tumors from forming new blood vessels, which the tumors need for growth. They target specific proteins that cancer cells frequently produce to promote their own proliferation. Thyroid tissue consists of follicular cells and parafollicular cells, where the cancer originates.

The primary categories of thyroid cancer medications encompass radioiodine ablation, thyroid-stimulating hormone (TSH) suppression, chemotherapy, targeted multikinase therapy, and additional options. Radioiodine ablation represents a form of radiation therapy that employs radioactive iodine to eliminate or ablate any remaining healthy thyroid tissue after a thyroidectomy. Various drugs in this space include ipilimumab, cabozantinib-s-malate, Caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, and others, which find application across settings like hospitals, oncology clinics, research organizations, and more.

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.